Literature DB >> 1703916

Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial.

M Merlano1, R Corvo, G Margarino, M Benasso, R Rosso, M R Sertoli, M Cavallari, M Scala, M Guenzi, A Siragusa.   

Abstract

Between 1983 and 1986, the National Institute for Cancer Research in Genoa and affiliated institutions conducted a randomized study to compare two different ways of combining chemotherapy (CT) and radiation therapy (RT). One hundred sixteen patients were randomized to receive neoadjuvant CT followed by definitive RT (treatment arm A) or alternating CT and RT. In treatment arm A, RT consisted of 70 Gy to the involved areas and 50 Gy to the uninvolved neck at 2 Gy/fraction, five fractions per week. In treatment arm B, RT consisted of 60 Gy to involved areas and 50 Gy to the uninvolved neck in three courses of 20 Gy each, 2 Gy/fraction, ten fractions/2 weeks alternated with four courses of CT. CT consisted of vinblastine 6 mg/m2 intravenously followed 6 hours later by bleomycin 30 IU intramuscularly, day 1; methotrexate 200 mg intravenously, day 2; leucovorin rescue, day 3. CT was repeated every 2 weeks up to four courses. The same CT was used in both treatment arms of the study. Fifty-five patients were entered in treatment arm A and 61 in treatment arm B. Complete responses were 7/48 and 19/57 in treatment arms A and B, respectively (P less than 0.03). Four-year progression-free survival was 4% in treatment arm A and 12% in treatment arm B (P less than 0.02), and four-year survival was 10% in A and 22% in B (P less than 0.02). Mucosal tolerance was significantly worse in treatment arm B (P less than 0.00004). The subgroup analysis shows the major improvement of alternating CT and RT in patients with the worst prognostic characteristics.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1703916     DOI: 10.1002/1097-0142(19910215)67:4<915::aid-cncr2820670410>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  Altered fractionation in the treatment of head and neck cancer.

Authors:  K S Hu; L B Harrison
Journal:  Curr Oncol Rep       Date:  1999       Impact factor: 5.075

2.  Intra-arterial high-dose chemotherapy with cisplatin as part of a palliative treatment concept in oral cancer.

Authors:  S Rohde; A F Kovács; B Turowski; B Yan; F Zanella; J Berkefeld
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

Review 3.  Head and neck cancer: guidelines for chemotherapy.

Authors:  G Catimel
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 4.  Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.

Authors:  Ambika Parmar; Michaelina Macluskey; Niall Mc Goldrick; David I Conway; Anne-Marie Glenny; Janet E Clarkson; Helen V Worthington; Kelvin Kw Chan
Journal:  Cochrane Database Syst Rev       Date:  2021-12-20

5.  Comparison of sequential chemoradiation with radiation alone in the treatment of advanced head and neck cancers.

Authors:  Sapna Manocha; Virender Suhag; B S Sunita; H S Hooda; S Singh
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2006-01

6.  Strategies for non-resectable head and neck cancer.

Authors:  Nerina Denaro; Elvio G Russi; Marco C Merlano
Journal:  Curr Treat Options Oncol       Date:  2013-12

7.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.

Authors:  Benjamin Lacas; Alexandra Carmel; Cécile Landais; Stuart J Wong; Lisa Licitra; Jeffrey S Tobias; Barbara Burtness; Maria Grazia Ghi; Ezra E W Cohen; Cai Grau; Gregory Wolf; Ricardo Hitt; Renzo Corvò; Volker Budach; Shaleen Kumar; Sarbani Ghosh Laskar; Jean-Jacques Mazeron; Lai-Ping Zhong; Werner Dobrowsky; Pirus Ghadjar; Carlo Fallai; Branko Zakotnik; Atul Sharma; René-Jean Bensadoun; Maria Grazia Ruo Redda; Séverine Racadot; George Fountzilas; David Brizel; Paolo Rovea; Athanassios Argiris; Zoltán Takácsi Nagy; Ju-Whei Lee; Catherine Fortpied; Jonathan Harris; Jean Bourhis; Anne Aupérin; Pierre Blanchard; Jean-Pierre Pignon
Journal:  Radiother Oncol       Date:  2021-01-27       Impact factor: 6.280

8.  Evaluation of neo-adjuvant, concurrent and adjuvant chemotherapy in the treatment of head and neck squamous cell carcinoma: a meta-analysis.

Authors:  Fahimeh Akhlaghi; Mohammad Esmaeelinejad; Amin Shams; Arsalan Augend
Journal:  J Dent (Tehran)       Date:  2014-05-31

9.  Results of concurrent radio-chemotherapy for the treatment of head and neck squamous cell carcinoma in everyday clinical practice with special reference to early mortality.

Authors:  Michael Schlumpf; Claude Fischer; Diana Naehrig; Christoph Rochlitz; Martin Buess
Journal:  BMC Cancer       Date:  2013-12-27       Impact factor: 4.430

10.  Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma.

Authors:  Sheng-Dean Luo; Yi-Ju Chen; Chien-Ting Liu; Kun-Ming Rau; Yi-Ching Chen; Hsin-Ting Tsai; Chang-Han Chen; Tai-Jan Chiu
Journal:  Biomed Res Int       Date:  2015-09-30       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.